Mebendazole and Melanoma: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Mebendazole and Melanoma: Latest Research 2026

This page summarizes the current state of scientific research on Mebendazole in the context of Melanoma as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your dermatologist or oncologist for personalized guidance.

Compound Overview

Mebendazole (Antiparasitic / Benzimidazole) — FDA-approved for human intestinal parasites; clinical trials ongoing for cancer

Mechanism of action: Inhibits tubulin polymerization; inhibits VEGFR2 angiogenesis; activates TRAIL-induced apoptosis

Current evidence level: Phase I/II clinical trials completed (glioblastoma, colorectal); favorable safety data

2026 Research Landscape

Research has directly examined Mebendazole in Melanoma, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Mebendazole affects the biological pathways involved in Melanoma progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Mebendazole in Melanoma patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Mebendazole[tiab]) AND (Melanoma[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Mebendazole keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Mebendazole + Melanoma research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Melanoma patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Mebendazole for Melanoma?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Mebendazole Melanoma' filtered to the last 2 years. The current evidence level is: Phase I/II clinical trials completed (glioblastoma, colorectal); favorable safety data.

Are there any 2025-2026 clinical trials for Mebendazole in Melanoma?

Check ClinicalTrials.gov with 'Mebendazole' as intervention and 'Melanoma' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your dermatologist or oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Mebendazole in Melanoma changed recently?

The field evolves rapidly. The current evidence classification is: Phase I/II clinical trials completed (glioblastoma, colorectal); favorable safety data. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.